Correspondence re: M. Provencio, et al. the topoisomerase IIa expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin. Cancer Res., 9: 1406-1411, 2003.
Vassilakopoulos
Theodoros P
TP
Angelopoulou
Maria K
MK
Siakantaris
Marina P
MP
Pangalis
Gerassimos A
GA
Kittas
Christos
C
Doussis-Anagnostopoulou
Ipatia
I
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use*; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D004268:DNA-Binding Proteins; D003606:Dacarbazine / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D014747:Vinblastine / Q000627:therapeutic use*
D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D004250:DNA Topoisomerases, Type II